Table 2

Follow up after mustine treatment in 20 children with LCH

Patient no.	Follow up after start of mustine (mth)	Current medication	Disease state (involved organ if not skin)	Residual defects	Skin findings
1	18	M	SD	—	Draining skin sinuses, scars
2	99	DDAVP	NAD	DI	Scars
3	57	0	NAD	—	Postinflammatory hyperpigmentation
4	53	DDAVP	NAD	DI	—
5	28	0	NAD	—	Scars, mild scaling
6	176	P^*	PD	—	New lesions (buttocks, ears), scars
7	33	DDAVP, GH	RD	DI, GHD	Scalp rash
8	159	DDAVP	RD	DI	Mild scalp rash
9	176	0	NAD	—	—
10	34	VB, P^†	PD (bone)	—	—
11	44	P^†, GH	PD (GI)	GHD, deafness	—
12	72	DDAVP, GH	RD	DI, GHD	Mild scalp rash
13	191	DDAVP, GH	NAD	DI, GHD	—
14	171	DDAVP, GH	NAD	DI, GHD	—
15	141	0	NAD	—	—
16	169	DDAVP	NAD	DI, GHD, hydrocephalus	Scars
17	149	0	NAD	DI, GHD, deafness	—
18	48	Cyt	PD (BM, LN)	Died	Persistent lesions (scalp, ears, gingiva), scars
19	156	0	RD	Deafness	Mild scalp rash, faint scars
20	17	0	RD	—	Mild scalp rash

M, mustine; P^*, low dose prednisolone on alternate days; P^†, 10 mg prednisolone daily; DDAVP, desamino-desarginino-vasopressin; GH, growth hormone. NAD, non-active disease; RD, regressing disease; SD, stable disease; PD, progressive disease. BM, bone marrow; LN, lymph node; GI, gastrointestinal involvement; DI, diabetes insipidus; GHD, growth hormone deficiency.